Pharmaceutical Industry adopts AMPS FDAECG Suite

AMPS llc is proud to announce that in the last few months, several leading Pharmaceutical corporations have acquired the AMPS FDAECG Suite for their ECG quality assessment. Among others AstraZeneca, Johnson & Johnson and Novartis have adopted the AMPS FDAECG Suite solution for the validation of HL7 files and noise quality assessment.

The AMPS FDAECG suite is the last product that has entered the AMPS portfolio, officially in October 2007.

The Suite is a new HL7 XML viewer that replaces and extends the previous XMLFDA Full Functional viewer from AMPS.  Noteworthy extensions are the validation and scoring modules for the HL7 XML ECG traces.
The validation module verifies that both the structure and content of the HL7 XML files meet the requirements embodied in the HL7 Schema and the HL7 Implementation Guide endorsed by the FDA.   Thanks to the strategic alliance signed with Mortara Instruments Inc. in August 2006, the FDAECG Suite and the FDA ECG Warehouse produce a consistent set of syntactical warnings and error messages during the validation phase thus giving a consistent interpretation of the HL7 XML standard requirements.
The AMPS FDAECG suite scoring module measures the quality of the loaded ECGs. The Suite includes several predefined metrics that calculate the high and low frequency noise using non parametric algorithms, and in addition different user level metrics may be easily created by the customers using the SDK tool provided by AMPS with the product.

AMPS llc, based in New York, NY, is a leading edge software company providing software solutions used specifically by Clinical Research Organizations and Pharmaceutical corporations in the field of quantitative ECG analysis and blood pressure monitoring. The company’s website is www.amps-llc.com.